Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeki Ito

Showing results (111-120 of 142) with videos related to

Pageof 15
Sort By:
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 4, 2021
[Treatment of secondary engraftment failure with granulocyte colony-stimulating factor and eltrombopag after allogeneic peripheral blood stem cell transplantation in adult T-cell leukemia/lymphoma]Kazuki Kiyohara, Norifumi Sugawara, Takahiro Maeta, et al.
International Journal of Hematology|February 9, 2017
Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology ForumHisayuki Yokoyama, Naoto Takahashi, Yuna Katsuoka, et al.
Transplantation and Cellular Therapy|May 14, 2021
Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell TransplantationMasaaki Hotta, Atsushi Satake, Hideaki Yoshimura, et al.
Annals of Nuclear Medicine|February 22, 2012
Improvement of the (99m)Tc-ECD brain uptake ratio (BUR) method for measurement of cerebral blood flowShigeki Ito, Akihiro Takaki, Shinya Inoue, et al.
International Journal of Hematology|January 6, 2026
Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trialKazutaka Sunami, Hiroshi Handa, Michiko Ichii, et al.
International Journal of Hematology|June 29, 2016
Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorizationNatsuko Takahashi, Junichi Kameoka, Naoto Takahashi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 14, 2025
Dismal Outcome of EBV-Positive Nodal T/NK-Cell Lymphoma: A Multicenter Retrospective StudySatoshi Ichikawa, Noriko Fukuhara, Yuna Katsuoka, et al.
International Journal of Hematology|November 9, 2019
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in JapanKohmei Kubo, Mitsuo Hori, Kensuke Ohta, et al.
International Journal of Hematology|December 17, 2025
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 studyShigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, et al.
International Journal of Hematology|May 16, 2022
Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysisKihyun Kim, Chang-Ki Min, Youngil Koh, et al.
Pageof 15

Showing results (111-120 of 142) with videos related to

Sort By:
Pageof 15
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 4, 2021
[Treatment of secondary engraftment failure with granulocyte colony-stimulating factor and eltrombopag after allogeneic peripheral blood stem cell transplantation in adult T-cell leukemia/lymphoma]Kazuki Kiyohara, Norifumi Sugawara, Takahiro Maeta, et al.
International Journal of Hematology|February 9, 2017
Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology ForumHisayuki Yokoyama, Naoto Takahashi, Yuna Katsuoka, et al.
Transplantation and Cellular Therapy|May 14, 2021
Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell TransplantationMasaaki Hotta, Atsushi Satake, Hideaki Yoshimura, et al.
Annals of Nuclear Medicine|February 22, 2012
Improvement of the (99m)Tc-ECD brain uptake ratio (BUR) method for measurement of cerebral blood flowShigeki Ito, Akihiro Takaki, Shinya Inoue, et al.
International Journal of Hematology|January 6, 2026
Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trialKazutaka Sunami, Hiroshi Handa, Michiko Ichii, et al.
International Journal of Hematology|June 29, 2016
Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorizationNatsuko Takahashi, Junichi Kameoka, Naoto Takahashi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 14, 2025
Dismal Outcome of EBV-Positive Nodal T/NK-Cell Lymphoma: A Multicenter Retrospective StudySatoshi Ichikawa, Noriko Fukuhara, Yuna Katsuoka, et al.
International Journal of Hematology|November 9, 2019
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in JapanKohmei Kubo, Mitsuo Hori, Kensuke Ohta, et al.
International Journal of Hematology|December 17, 2025
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 studyShigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, et al.
International Journal of Hematology|May 16, 2022
Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysisKihyun Kim, Chang-Ki Min, Youngil Koh, et al.
Pageof 15